Measurement of Free Plasma Concentrations of Beta-Lactam Antibiotics: An Applicability Study in Intensive Care Unit Patients.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
13
07
2020
accepted:
29
09
2020
pubmed:
22
10
2020
medline:
16
11
2021
entrez:
21
10
2020
Statut:
ppublish
Résumé
The antibacterial effect of antibiotics is linked to the free drug concentration. This study investigated the applicability of an ultrafiltration method to determine free plasma concentrations of beta-lactam antibiotics in ICU patients. Eligible patients included adult ICU patients treated with ceftazidime (CAZ), meropenem (MEM), piperacillin (PIP)/tazobactam (TAZ), or flucloxacillin (FXN) by continuous infusion. Up to 2 arterial blood samples were drawn at steady state. Patients could be included more than once if they received another antibiotic. Free drug concentrations were determined by high-performance liquid chromatography with ultraviolet detection after ultrafiltration, using a method that maintained physiological conditions (pH 7.4/37°C). Total drug concentrations were determined to calculate the unbound fraction. In a post-hoc analysis, free concentrations were compared with the target value of 4× the epidemiological cut-off value (ECOFF) for Pseudomonas aeruginosa as a worst-case scenario for empirical therapy with CAZ, MEM or PIP/tazobactam and against methicillin-sensitive Staphylococcus aureus for targeted therapy with FXN. Fifty different antibiotic treatment periods in 38 patients were evaluated. The concentrations of the antibiotics showed a wide range because of the fixed dosing regimen in a mixed population with variable kidney function. The mean unbound fractions (fu) of CAZ, MEM, and PIP were 102.5%, 98.4%, and 95.7%, with interpatient variability of <6%. The mean fu of FXN was 11.6%, with interpatient variability of 39%. It was observed that 2 of 12 free concentrations of CAZ, 1 of 40 concentrations of MEM, and 11 of 23 concentrations of PIP were below the applied target concentration of 4 × ECOFF for P. aeruginosa. All concentrations of FXN (9 samples from 6 patients) were >8 × ECOFF for methicillin-sensitive Staphylococcus aureus. For therapeutic drug monitoring purposes, measuring total or free concentrations of CAZ, MEM, or PIP is seemingly adequate. For highly protein-bound beta-lactams such as FXN, free concentrations should be favored in ICU patients with prevalent hypoalbuminemia.
Sections du résumé
BACKGROUND
The antibacterial effect of antibiotics is linked to the free drug concentration. This study investigated the applicability of an ultrafiltration method to determine free plasma concentrations of beta-lactam antibiotics in ICU patients.
METHODS
Eligible patients included adult ICU patients treated with ceftazidime (CAZ), meropenem (MEM), piperacillin (PIP)/tazobactam (TAZ), or flucloxacillin (FXN) by continuous infusion. Up to 2 arterial blood samples were drawn at steady state. Patients could be included more than once if they received another antibiotic. Free drug concentrations were determined by high-performance liquid chromatography with ultraviolet detection after ultrafiltration, using a method that maintained physiological conditions (pH 7.4/37°C). Total drug concentrations were determined to calculate the unbound fraction. In a post-hoc analysis, free concentrations were compared with the target value of 4× the epidemiological cut-off value (ECOFF) for Pseudomonas aeruginosa as a worst-case scenario for empirical therapy with CAZ, MEM or PIP/tazobactam and against methicillin-sensitive Staphylococcus aureus for targeted therapy with FXN.
RESULTS
Fifty different antibiotic treatment periods in 38 patients were evaluated. The concentrations of the antibiotics showed a wide range because of the fixed dosing regimen in a mixed population with variable kidney function. The mean unbound fractions (fu) of CAZ, MEM, and PIP were 102.5%, 98.4%, and 95.7%, with interpatient variability of <6%. The mean fu of FXN was 11.6%, with interpatient variability of 39%. It was observed that 2 of 12 free concentrations of CAZ, 1 of 40 concentrations of MEM, and 11 of 23 concentrations of PIP were below the applied target concentration of 4 × ECOFF for P. aeruginosa. All concentrations of FXN (9 samples from 6 patients) were >8 × ECOFF for methicillin-sensitive Staphylococcus aureus.
CONCLUSIONS
For therapeutic drug monitoring purposes, measuring total or free concentrations of CAZ, MEM, or PIP is seemingly adequate. For highly protein-bound beta-lactams such as FXN, free concentrations should be favored in ICU patients with prevalent hypoalbuminemia.
Identifiants
pubmed: 33086362
pii: 00007691-202104000-00010
doi: 10.1097/FTD.0000000000000827
doi:
Substances chimiques
Anti-Bacterial Agents
0
Piperacillin, Tazobactam Drug Combination
157044-21-8
Floxacillin
43B2M34G2V
Ceftazidime
9M416Z9QNR
Meropenem
FV9J3JU8B1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
264-270Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). Crit Care. 2019;23:104.
Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52:1–8.
Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55:601–607.
McAleenan A, Ambrose PG, Bhavnani SM, et al. Methodological features of clinical pharmacokinetic–pharmacodynamic studies of antibacterials and antifungals: a systematic review. J Antimicrob Chemother. 2020;75:1374–1389.
Musteata FM. Measuring and using free drug concentrations: has there been “real” progress? Bioanalysis. 2017;9:767–769.
Zhang F, Xue J, Shao J, et al. Compilation of 222 drugs' plasma protein binding data and guidance for study designs. Drug Discov Today. 2012;17:475–485.
Kratzer A, Liebchen U, Schleibinger M, et al. Determination of free vancomycin, ceftriaxone, cefazolin and ertapenem in plasma by ultrafiltration: impact of experimental conditions. J Chromatogr B. 2014;961:97–102.
Nilsson LB. The bioanalytical challenge of determining unbound concentration and protein binding for drugs. Bioanalysis. 2013;5:3033–3050.
Kratzer A, Kees F, Dorn C. Unbound fraction of fluconazole and linezolid in human plasma as determined by ultrafiltration: impact of membrane type. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1039:74–78.
Kratzer A, Schießer S, Matzneller P, et al. Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV. J Pharm Biomed Anal. 2019;163:34–38.
Dorn C, Schießer S, Wulkersdorfer B, et al. Determination of free clindamycin, flucloxacillin or tedizolid in plasma: pay attention to physiological conditions when using ultrafiltration. Biomed Chromatogr. 2020;34:e4820.
Dorn C, Kratzer A, Liebchen U, et al. Impact of experimental variables on the protein binding of tigecycline in human plasma as determined by ultrafiltration. J Pharm Sci. 2017;102:739–744.
Stove V, Coene L, Carlier M, et al. Measuring unbound versus total vancomycin concentrations in serum and plasma: methodological issues and relevance. Ther Drug Monit. 2015;37:180–187.
McWhinney BC, Wallis SC, Hillister T, et al. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2039–2043.
European Medicines Agency (EMA). Guideline on Bioanalytical Method Validation. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf . Accessed April 6, 2020.
Kees F, Raasch W, Steger M, et al. High-performance liquid chromatographic assay for cefotiam and d3-cefotiam in human serum. J Chromatogr. 1990;525:484–489.
Dhaese SA, Farkas A, Colin P, et al. Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. J Antimicrob Chemother. 2019;74:432–441.
The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 10.0. Available at: http://www.eucast.org . Accessed April 6, 2020.
Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. New Engl J Med. 2012;367:20–29.
SPC Floxapen 1000 mg Powder for Solution for Injection or Infusion. Available at: https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA1380-011-007_14122018154637.pdf . Accessed April 6, 2020.
Muller AE, Huttner B, Huttner A. Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections? Drugs. 2018;78:439–451.
Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care. 2007;13:598–606.
Richards DM, Brogden RN. Ceftazidime. Drugs. 1985;29:105–161.
Bulitta JB, Landersdorfer CB, Hüttner SJ, et al. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 2010;54:1275–1282.
van Dalen R, Vree TB, Baars AM, et al. Dosage adjustment for ceftazidime in patients with impaired renal function. Eur J Clin Pharmacol. 1986;30:597–605.
Mouton JW, Horrevorts AM, Mulder PG, et al. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother. 1990;34:2307–2311.
Lam YW, Duroux MH, Gambertoglio JG, et al. Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers. Antimicrob Agents Chemother. 1988;32:298–302.
Matzke GR, Frye RF, Joy MS, et al. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother. 2000;44:1639–1644.
Verhagen CA, Mattie H, Strijen EV. The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion. Br J Clin Pharmacol. 1994;37:193–197.
Naicker S, Guerra Valero YC, Ordenez Meija JL, et al. A UHPLC–MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. J Pharm Biomed Anal. 2018;148:324–333.
Colman S, Stove V, Waele JD, et al. Measuring unbound versus total piperacillin concentrations in plasma of critically ill patients. Ther Drug Monit. 2019;41:325–330.
Li Z, Li Q, Wang Y, et al. Determination of free and total piperacillin–tazobactam in plasma by HPLC–MS–MS: an adapted method for neonates. Chromatographia. 2012;41:1–7.
Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis Suppl. 1995;96:11–16.
Al-Shaer MH, Alghamdi WA, Graham E, et al. Meropenem, cefepime, and piperacillin protein binding in patient samples. Ther Drug Monit. 2020;42:129–132.
Chin PKL, Drennan PG, Gardiner SJ, et al. Total flucloxacillin plasma concentrations poorly reflect unbound concentrations in hospitalized patients with Staphylococcus aureus bacteraemia. Br J Clin Pharmacol. 2018;84:2311–2316.
Ulldemolins M, Roberts JA, Wallis SC, et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother. 2010;65:1771–1778.
Burkhardt O, Kumar V, Katterwe D, et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother. 2007;59:277–284.
Burkhardt O, Kumar V, Schmidt S, et al. Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations. Int J Antimicrob Agents. 2010;35:96–97.
Garot D, Respaud R, Lanotte P, et al. Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol. 2011;72:758–767.
Liebchen U, Kratzer A, Wicha SG, et al. Unbound fraction of ertapenem in intensive care unit patients. J Antimicrob Chemother. 2014;69:3108–3111.
Schleibinger M, Steinbach CL, Töpper C, et al. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. Br J Clin Pharmacol. 2015;80:525–533.
Boidin C, Moshiri P, Dahyot-Fizelier C, et al. Pharmacokinetic variability of beta-lactams in critically ill patients: a narrative review. Anaesth Crit Care Pain Med. 2020;39:87–109.
Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care. 2011;15:R206.
Hatti M, Solomonidi N, Odenholt I, et al. Considerable variation of trough β-lactam concentrations in older adults hospitalized with infection-a prospective observational study. Eur J Clin Microbiol Infect Dis. 2018;37:485–493.
Angrill N, Gallego M, Font J, et al. Determinants of empirical antipseudomonal antibiotic prescription for adults with pneumonia in the emergency department. BMC Pulm Med. 2020;20:83.
Eagye KJ, Banevicius MA, Nicolau DP. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy. Crit Care Med. 2012;40:1329–1332.
Gudiol C, Cuervo G, Carratalà J. Optimizing therapy of bloodstream infection due to extended-spectrum β-lactamase-producing enterobacteriaceae. Curr Opin Crit Care. 2019;25:438–448.
Dhaese SA, Thooft AD, Farkas A, et al. Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: a prospective observational study. J Crit Care. 2019;52:75–79.
Klastrup V, Thorsted A, Storgaard M, et al. Population pharmacokinetics of piperacillin following continuous infusion in critically ill patients: impact of renal function on target attainment. Antimicrob Agents Chemother. 2020;64:e02556–e02619.
Delattre IK, Taccone FS, Jacobs F, et al. Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? Expert Rev Anti Infect Ther. 2017;15:677–688.
Grahl JJ, Stollings JL, Rakhit S, et al. Antimicrobial exposure and the risk of delirium in critically ill patients. Crit Care. 2018;22:337.
Imani S, Buscher H, Marriott D, et al. Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships. J Antimicrob Chemother. 2017;72:2891–2897.
Quinton MC, Bodeau S, Kontar L, et al. Neurotoxic concentration of piperacillin during continuous infusion in critically ill patients. Antimicrob Agents Chemother. 2017;61:e00654–e00717.
Donadello K, Antonucci E, Cristallini S, et al. β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: a case-control study. Int J Antimicrob Agents. 2015;45:278–282.